Fenofibrate attenuates impaired ischemic preconditioning-mediated cardioprotection in the fructose-fed hypertriglyceridemic rat heart

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 386, Issue 4, 2013, Pages 319-329

  Babbar, Lalita ^a   Mahadevan, Nanjaian ^a   Balakumar, Pitchai ^a  

^a Rajendra Institute of Technology and Sciences   (India)

Author keywords

Fructose feeding; Hypertriglyceridemia; Ischemic preconditioning; Myocardial I R injury

Indexed keywords

CREATINE KINASE MB; FENOFIBRATE; FRUCTOSE; LACTATE DEHYDROGENASE; TRIACYLGLYCEROL; TRIPHENYLTETRAZOLIUM; WORTMANNIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; HEART INFARCTION SIZE; HEART INJURY; HEART PROTECTION; HYPERTRIGLYCERIDEMIA; ISCHEMIC PRECONDITIONING; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; REPERFUSION INJURY;

ANIMALS; CHOLESTEROL; CREATINE KINASE, MB FORM; FENOFIBRATE; FRUCTOSE; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; L-LACTATE DEHYDROGENASE; MALE; MYOCARDIAL REPERFUSION INJURY; OXIDATIVE STRESS; RATS; RATS, WISTAR; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 84876419814     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-012-0830-3     Document Type: Article

References (62)

1. Ascaso JF, Millán J, Mateo-Gallego R, Ruiz A, Suarez-Tembra M, Borrallo RM, Zambon D, Gonzalez-Santos P, Peres-de-Juan M, Ros E, Hypertriglyceridemia Registry of Spanish Arteriosclerosis Society (2011) Prevalence of metabolic syndrome and cardiovascular disease in a hypertriglyceridemic population. Eur J Intern Med 22:177-181
2. Balakumar P, Babbar L (2012) Preconditioning the hyperlipidemic myocardium: fact or fantasy? Cell Signal 24:589-595
3. Balakumar P, Sharma NK (2012) Healing the diabetic heart: does myocardial preconditioning work? Cell Signal 24:53-59
4. Balakumar P, Rohilla A, Singh M (2008) Pre-conditioning and postconditioning to limit ischemia reperfusion-induced myocardial injury: what could be the next footstep? Pharmcol Res 57:403-412
5. Balakumar P, Singh H, Reddy K, Anand-Srivastava MB (2009a) Adenosine-A1 receptors activation restores the suppressed cardioprotective effects of ischemic preconditioning in hyperhomocysteinemic rat hearts. J Cardiovasc Pharmacol 54:204-212
6. Balakumar P, Singh H, Singh M, Anand-Srivastava MB (2009b) The impairment of preconditioning-mediated cardioprotection in pathological conditions. Pharmacol Res 60:18-23
7. Balakumar P, Rohilla A, Singh G, Singh K, Singh M (2009c) Modulation of cardioprotective effect of ischemic pre- and postconditioning in the hyperhomocysteinemic rat heart. Methods Find Exp Clin Pharmacol 31:71-79
8. Balakumar P, Rohilla A, Mahadevan N (2011) Pleiotropic actions of fenofibrate on the heart. Pharmacol Res 63:8-12
9. Ban K, Cooper AJ, Samuel S, Bhatti A, Patel M, Izumo S, Penninger JM, Backx PH, Oudit GY, Tsushima RG (2008) Phosphatidylinositol 3-kinase gamma is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning. Circ Res 103:643-653
10. Boyne AF, Ellman GL (1972) A methodology for analysis of tissue sulfhydryl components. Anal Biochem 46:639-653
11. Briones AM, Touyz RM (2010) Oxidative stress and hypertension: current concepts. Curr Hypertens Rep 12:135-142
12. Bulhak AA, Sjöquist PO, Xu CB, Edvinsson L, Pernow J (2006) Protection against myocardial ischaemia/reperfusion injury by PPAR-alpha activation is related to production of nitric oxide and endothelin-1. Basic Res Cardiol 101:244-252
13. Bulhak AA, Jung C, Ostenson CG, Lundberg JO, Sjöquist PO, Pernow J (2009) PPAR-alpha activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-kinase/Akt and NO pathway. Am J Physiol Heart Circ Physiol 296:H719-727
14. Cao CM, Zhang Y, Weisleder N, Ferrante C, Wang X, Lv F, Zhang Y, Song R, Hwang M, Jin L, Guo J, Peng W, Li G, Nishi M, Ma J, Xiao RP (2010) MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation 121:2565-2574
15. Cárdenas G, Torres JC, Zamora J, Baños G (2005) Isolated heart function during ischemia and reperfusion in sucrose-fed rats: effect of insulin infusion. Cardiovasc Pathol 14:256-264
16. Carvajal K, Baños G (2002) Myocardial function and effect of serum in isolated heart from hypertriglyceridemic and hypertensive rats. Clin Exp Hypertens 24:235-248
17. Carvajal K, El Hafidi M, Baños G (1999) Myocardial damage due to ischemia and reperfusion in hypertriglyceridemic and hypertensive rats: participation of free radicals and calcium overload. J Hypertens 17:1607-1616
18. Chopra K, Singh M, Kaul N, Andrabi KI, Ganguly NK (1992) Decrease of myocardial infarct size with desferrioxamine: possible role of oxygen free radicals in its ameliorative effect. Mol Cell Biochem 113:71-76
19. Churchill EN, Ferreira JC, Brum PC, Szweda LI, Mochly-Rosen D (2010) Ischaemic preconditioning improves proteasomal activity and increases the degradation of delta PKC during reperfusion. Cardiovasc Res 85:385-394
20. Cullen P (2000) Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 86:943-949
21. Ebrahim Z, Yellon DM, Baxter GF (2007) Ischemic preconditioning is lost in aging hypertensive rat heart: independent effects of aging and longstanding hypertension. Exp Gerontol 42:807-814
22. Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70-77
23. el-Remessy AB, Bartoli M, Platt DH, Fulton D, Caldwell RB (2005) Oxidative stress inactivates VEGF survival signaling in retinal endothelial cells via PI3-kinase tyrosine nitration. J Cell Sci 118:243-252
24. Ferdinandy P, Schulz R (2003) Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 138:532-543
25. Ferdinandy P, Schulz R, Baxter GF (2007) Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59:418-458
26. Fishbein MC, Meerbaum S, Rit J, Lando U, Kanmatsuse K, Mercier JC, Corday E, Ganz W (1981) Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J 101:593-600
27. Fried SK, Rao SP (2003) Sugars, hypertriglyceridemia, and cardiovascular disease. Am J Clin Nutr 78:873S-880S
28. Huang XS, Zhao SP, Bai L, Hu M, Zhao W, Zhang Q (2009) Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha. Br J Pharmacol 158:706-712
29. Jenkins DP, Pugsley WB, Alkhulaifi AM, Kemp M, Hooper J, Yellon DM (1997) Ischaemic preconditioning reduces troponin T release in patients undergoing coronary artery bypass surgery. Heart 77:314-318
30. Jordan JE, Simandle SA, Tulbert CD, Busija DW, Miller AW (2003) Fructose-fed rats are protected against ischemia/reperfusion injury. J Pharmacol Exp Ther 307:1007-1011
31. Joyeux-Faure M, Rossini E, Ribuot C, Faure P (2006) Fructose-fed rat hearts are protected against ischemia-reperfusion injury. Exp Biol Med (Maywood) 231:456-462
32. Kalra BS, Roy V (2012) Efficacy of metabolic modulators in ischemic heart disease: an overview. J Clin Pharmacol 52:292-305
33. Kaur H, Parikh V, Sharma A, Singh M (1997) Effect of amiloride A Na+/H + exchange inhibitor on cardioprotective effect of ischaemic preconditioning: possible involvement of resident cardiac mast cells. Pharmacol Res 36:95-102
34. Kersten JR, Toller WG, Gross ER, Pagel PS, Warltier DC (2000) Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am J Physiol Heart Circ Physiol 278:H1218-1224
35. Kloner RA, Jennings RB (2001) Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 2. Circulation 104:3158-3167
36. Kocsis GF, Csont T, Varga-Orvos Z, Puskas LG, Murlasits Z, Ferdinandy P (2010) Expression of genes related to oxidative/nitrosative stress in mouse hearts: effect of preconditioning and cholesterol diet. Med Sci Monit 16:BR32-39
37. Langendorff O (1895) Untersuchungen am uberlebenden Saugethierherzen. Pflugers Archiv 61:291-332
38. Lochner A, Marais E, Genade S, Huisamen B, du Toit EF, Moolman JA (2009) Protection of the ischaemic heart: investigations into the phenomenon of ischaemic preconditioning. Cardiovasc J Afr 20:43-51
39. Lotz C, Lazariotto M, Redel A, Smul TM, Stumpner J, Blomeyer C, Tischer-Zeitz T, Schmidt J, Pociej J, Roewer N, Kehl F, Lange M (2011) Activation of peroxisome-proliferator-activated receptors α and γ mediates remote ischemic preconditioning against myocardial infarction in vivo. Exp Biol Med (Maywood) 236:113-122
40. Ma FX, Liu LY, Xiong XM (2003) Protective effects of lovastatin on vascular endothelium injured by low density lipoprotein. Acta Pharmacol Sin 24:1027-1032
41. Mocanu MM, Bell RM, Yellon DM (2002) PI3 kinase and not p42/p44 appears to be implicated in the protection conferred by ischemic preconditioning. J Mol Cell Cardiol 34:661-668
42. Murry CE, Jennings RB, Reimer KA (1986) Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74:1124-1136
43. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A (2007) Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298:299-308
44. Ohkawa H, Ohishi N, Ya K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical Biochem 95:351-358
45. Osipov RM, Bianchi C, Feng J, Clements RT, Liu Y, Robich MP, Glazer HP, Sodha NR, Sellke FW (2009) Effect of hypercholesterolemia on myocardial necrosis and apoptosis in the setting of ischemia-reperfusion. Circulation 120:S22-30
46. Parikh V, Singh M (1999) Possible role of adrenergic component and cardiac mast cell degranulation in preconditioning-induced cardioprotection. Pharmacol Res 40:129-137
47. Penna C, Alloatti G, Cappello S, Gattullo D, Berta G, Mognetti B, Losano G, Pagliaro P (2005) Platelet-activating factor induces cardioprotection in isolated rat heart akin to ischemic preconditioning: role of phosphoinositide 3-kinase and protein kinase C activation. Am J Physiol Heart Circ Physiol 288:H2512-2520
48. Perrelli MG, Pagliaro P, Penna C (2011) Ischemia/reperfusion injury and cardioprotective mechanisms: role of mitochondria and reactive oxygen species. World J Cardiol 3:186-200
49. Ravingerová T, Matejíková J, Neckár J, Andelová E, Kolár F (2007) Differential role of PI3K/Akt pathway in the infarct size limitation and antiarrhythmic protection in the rat heart. Mol Cell Biochem 297:111-120
50. Roglans N, Sanguino E, Peris C, Alegret M, Vázquez M, Adzet T, Díaz C, Hernández G, Laguna JC, Sánchez RM (2002) Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. J Pharmacol Exp Ther 302:232-239
51. Rohilla A, Singh G, Singh M, Bala kumar P (2010) Possible involvement of PKC-delta in the abrogated cardioprotective potential of ischemic preconditioning in hyperhomocysteinemic rat hearts. Biomed Pharmacother 64:195-202
52. Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW (2007) Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 30:1945-1951
53. Sánchez-Lozada LG, Tapia E, Jiménez A, Bautista P, Cristóbal M, Nepomuceno T, Soto V, Avila-Casado C, Nakagawa T, Johnson RJ, Herrera-Acosta J, Franco M (2007) Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. Am J Physiol Renal Physiol 292:F423-429
54. Sharma A, Singh M (2000) Possible mechanism of cardioprotective effect of ischaemic preconditioning in isolated rat heart. Pharmacol Res 41:635-640
55. Sharma NK, Mahadevan N, Balakumar P (2012) Adenosine transport blockade restores attenuated cardioprotective effects of adenosine preconditioning in the isolated diabetic rat heart: Potential crosstalk with opioid receptors. Cardiovasc Toxicol. doi: 10.1007/s12012-012-9182-y
56. Tabernero A, Schoonjans K, Jesel L, Carpusca I, Auwerx J, Andriantsitohaina R (2002) Activation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation. BMC Pharmacol 2:10
57. Taleb-Dida N, Krouf D, Bouchenak M (2011) Globularia alypum aqueous extract decreases hypertriglyceridemia and ameliorates oxidative status of the muscle, kidney, and heart in rats fed a high-fructose diet. Nutr Res 31:488-495
58. Uchida A, Slipchenko MN, Cheng JX, Buhman KK (2011) Fenofibrate, a peroxisome proliferator-activated receptor α agonist, alters triglyceride metabolism in enterocytes of mice. Biochim Biophys Acta 1811:170-176
59. Yellon DM, Downey JM (2003) Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 83:1113-1151
60. Yellon DM, Alkhulaifi AM, Pugsley WB (1993) Preconditioning the human myocardium. Lancet 342:276-277
61. Yue TL, Bao W, Jucker BM, Gu JL, Romanic AM, Brown PJ, Cui J, Thudium DT, Boyce R, Burns-Kurtis CL, Mirabile RC, Aravindhan K, Ohlstein EH (2003) Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation 108:2393-2399
62. Zhang N, Wang XH, Mao SL, Zhao F (2011) Astragaloside IV improves metabolic syndrome and endothelium dysfunction in fructose-fed rats. Molecules 16:3896-3907